CVS Group (LON:CVSG) Posts Earnings Results

CVS Group (LON:CVSG) released its quarterly earnings data on Thursday. The company reported GBX 85.60 earnings per share (EPS) for the quarter, Digital Look Earnings reports. CVS Group had a return on equity of 5.91% and a net margin of 2.43%.

Here are the key takeaways from CVS Group’s conference call:

• Revenue rose 5.9% to £712.8 million and adjusted EBITDA increased 5.1% to £141.5 million, with the margin maintained at 19.9% despite inflationary pressures. Adjusted EPS grew 6.9% to 85.6 pence.
• Like-for-like revenue growth was 2.1%, below the company’s 4%–8% target, as weaker U.K. consumer confidence and unusually hot weather reduced routine appointments and delayed procedures. Management said trading has since returned to pre-heatwave levels and expects to perform in line with market expectations.
• CVS completed a refinancing that provides £350 million of committed facilities through May 2030 on improved terms, while leverage remained below its 2.0x threshold at 1.63x. The company is also progressing with a £50 million share buyback expected to finish within the next couple of months.
• Australia remains a key expansion opportunity, contributing about £20 million of EBITDA excluding central costs, with further Australian and U.K. acquisitions signed or completed since year-end. Management expects to invest around £50 million annually in acquisitions while remaining selective on valuation.
• Organic growth initiatives include the Healthy Pet Club Advanced subscription, which had attracted approximately 14,500 clients shortly after launch, alongside digital booking, CRM, AI consultation tools, and improved client communications. Capital expenditure is expected to moderate to about £30 million annually, potentially freeing cash for acquisitions or shareholder returns.

CVS Group Price Performance

CVS Group stock traded down GBX 13 during midday trading on Friday, hitting GBX 1,208. 436,037 shares of the company’s stock were exchanged, compared to its average volume of 879,295. CVS Group has a 52-week low of GBX 1,062 and a 52-week high of GBX 1,648. The stock has a 50-day moving average price of GBX 1,287.09 and a two-hundred day moving average price of GBX 1,229.43. The company has a debt-to-equity ratio of 110.41, a quick ratio of 0.90 and a current ratio of 1.18. The company has a market cap of £821.08 million, a P/E ratio of 17.53, a PEG ratio of 1.77 and a beta of 1.07.

Analyst Upgrades and Downgrades

CVSG has been the subject of a number of recent analyst reports. Berenberg Bank reaffirmed a “buy” rating and set a GBX 2,000 target price on shares of CVS Group in a report on Thursday. Shore Capital Group reissued a “hold” rating and issued a GBX 1,400 price target on shares of CVS Group in a report on Thursday. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,700 price objective on shares of CVS Group in a research report on Monday, July 27th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a GBX 1,400 price objective on shares of CVS Group in a research note on Friday. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of GBX 1,666.67.

Insiders Place Their Bets

In other CVS Group news, insider Robin Alfonso acquired 768 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was bought at an average price of GBX 1,294 per share, with a total value of £9,937.92. Also, insider David Wilton acquired 1,500 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were acquired at an average cost of GBX 1,276 per share, with a total value of £19,140. Insiders have acquired 3,860 shares of company stock worth $4,956,696 in the last ninety days. 1.48% of the stock is currently owned by insiders.

CVS Group News Roundup

Here are the key news stories impacting CVS Group this week:

• Positive Sentiment: Dividend supported by shareholder returns: CVS Group recommended a final dividend for the year ended June 30, 2026, payable on December 4, providing an income component for investors. CVS Group recommends final dividend
• Positive Sentiment: Insider purchase offers a modest confidence signal: Non-executive director Laura Hagan bought 4,128 CVS Group shares. The transaction may reassure investors about management’s view of the company’s valuation, although its financial impact is limited. CVS Group director share purchase
• Positive Sentiment: Berenberg maintained a Buy rating and a GBX 2,000 price target, implying substantial upside from the stock’s recent trading level. Berenberg rating update
• Neutral Sentiment: Full-year results were released: CVS Group reported GBX 85.60 in earnings per share, alongside a 2.31% net margin and 5.35% return on equity. The figures provide a fresh performance update, but the relatively low profitability metrics may limit enthusiasm without further detail on growth and costs. CVS Group full-year earnings results
• Negative Sentiment: Analyst caution remains the main pressure: Shore Capital reaffirmed its Hold rating and GBX 1,400 target, while Jefferies also maintained Hold with the same target. The repeated neutral recommendations suggest limited near-term conviction despite the higher Berenberg target. Shore Capital Hold rating

CVS Group Company Profile

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group operates from over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business (“Animed Direct”).

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.